CLEARPOINT NEURO, INC. Financials ClearPoint Neuro, Inc.
Equities
CLPT
US18507C1036
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.4 USD | +6.49% |
|
+6.84% | -5.74% |
| May. 07 | ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 175.5 | - | - |
| Enterprise Value (EV) 1 | 72.99 | 268.1 | 265.2 | 208 | 167.2 | 175.5 | 175.5 | 175.5 |
| P/E ratio | -11.4 x | -37 x | -16.3 x | -12.5 x | -7.54 x | -9.7 x | -10.3 x | -11.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 5.75 x | 4.16 x | 3.01 x |
| EV / Revenue | 6.51 x | 20.9 x | 16.3 x | 10.1 x | 6.98 x | 5.75 x | 4.16 x | 3.01 x |
| EV / EBITDA | - | -55.9 x | -23.8 x | -17.4 x | -10.6 x | -15.9 x | -19.6 x | -79.8 x |
| EV / FCF | - | -32.3 x | - | - | -11.6 x | -18.3 x | -54.5 x | - |
| FCF Yield | - | -3.09% | - | - | -8.64% | -5.46% | -1.84% | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15,206 | 16,870 | 23,640 | 24,555 | 24,621 | 27,420 | - | - |
| Reference price 2 | 4.800 | 15.89 | 11.22 | 8.470 | 6.790 | 6.400 | 6.400 | 6.400 |
| Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.22 | 12.83 | 16.3 | 20.55 | 23.96 | 30.52 | 42.22 | 58.3 |
| EBITDA 1 | - | -4.796 | -11.14 | -11.96 | -15.74 | -11.05 | -8.95 | -2.2 |
| EBIT 1 | - | -6.22 | -13.37 | -16.33 | -22.45 | -17.84 | -16.96 | -16 |
| Operating Margin | - | -48.48% | -82.05% | -79.47% | -93.7% | -58.44% | -40.16% | -27.44% |
| Earnings before Tax (EBT) 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -17.42 | -16.52 | -15.1 |
| Net income 1 | - | -6.782 | -14.41 | -16.44 | -22.09 | -17.42 | -16.52 | -15.1 |
| Net margin | - | -52.86% | -88.41% | -79.97% | -92.21% | -57.09% | -39.12% | -25.9% |
| EPS 2 | -0.4200 | -0.4300 | -0.6900 | -0.6800 | -0.9000 | -0.6600 | -0.6200 | -0.5500 |
| Free Cash Flow 1 | - | -8.29 | - | - | -14.44 | -9.581 | -3.222 | - |
| FCF margin | - | -64.62% | - | - | -60.27% | -31.39% | -7.63% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.3 | 5.031 | 5.2 | 5.146 | 5.174 | 5.433 | 5.95 | 5.762 | 6.81 | 7.639 | 7.33 | 7.565 | 7.946 |
| EBITDA 1 | -3.011 | -2.879 | -3.223 | -2.583 | -3.277 | -4.276 | -5.33 | -3.155 | -2.98 | -2.484 | -3.25 | -2.65 | -2.7 |
| EBIT 1 | -3.982 | -3.864 | -4.204 | -3.795 | -4.469 | -5.712 | -7.131 | -4.897 | -4.706 | -4.231 | -4.838 | -4.418 | -4.338 |
| Operating Margin | -92.6% | -76.8% | -80.85% | -73.75% | -86.37% | -105.14% | -119.85% | -84.99% | -69.1% | -55.39% | -66% | -58.4% | -54.59% |
| Earnings before Tax (EBT) 1 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.146 | -4.719 | -4.301 | -4.221 |
| Net income 1 | -4.149 | -3.959 | -4.303 | -3.788 | -4.385 | -5.609 | -7.052 | -4.809 | -4.619 | -4.146 | -4.719 | -4.301 | -4.221 |
| Net margin | -96.49% | -78.69% | -82.75% | -73.61% | -84.75% | -103.24% | -118.52% | -83.46% | -67.83% | -54.27% | -64.39% | -56.85% | -53.12% |
| EPS 2 | -0.1900 | -0.1700 | -0.1800 | -0.1500 | -0.1800 | -0.2300 | -0.2900 | -0.2000 | -0.1900 | -0.1600 | -0.1800 | -0.1633 | -0.1567 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/11/22 | 8/9/22 | 11/8/22 | 3/1/23 | 5/11/23 | 8/8/23 | 11/9/23 | 3/12/24 | 5/7/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -8.29 | - | - | -14.4 | -9.58 | -3.22 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | - | 0.72 | 0.19 | 0.25 | - |
| Capex / Sales | - | - | - | - | 2.99% | 0.62% | 0.6% | - |
| Announcement Date | 2/12/20 | 3/4/21 | 3/1/22 | 3/1/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.4
USD
Average target price
10
USD
Spread / Average Target
+56.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.74% | 175M | |
| +12.85% | 229B | |
| +13.88% | 195B | |
| +18.39% | 142B | |
| +28.78% | 109B | |
| +2.43% | 64.85B | |
| +18.24% | 54.33B | |
| +7.04% | 52.09B | |
| +10.83% | 45.15B | |
| +5.94% | 37.39B |
- Stock Market
- Equities
- CLPT Stock
- Financials ClearPoint Neuro, Inc.